Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Karl Belanger"'
Autor:
Arielle Elkrief, Layal El Raichani, Corentin Richard, Meriem Messaoudene, Wiam Belkaid, Julie Malo, Karl Belanger, Wilson Miller, Rahima Jamal, Nathalie Letarte, Philip Wong, Bertrand Routy
Publikováno v:
OncoImmunology, Vol 8, Iss 4 (2019)
Background: The gut microbiota has been shown to be an important determinant of the efficacy of immune checkpoint inhibitions (ICI) in cancer. Several lines of evidence suggest that antibiotic (ATB) usage prior to or within the first month of ICI ini
Externí odkaz:
https://doaj.org/article/c844f486957d4b01a1054413048b8e40
Autor:
Vivien Bramwell, Martin Blackstein, Karl Belanger, Shail Verma, Sandra Beare, Elizabeth Eisenhauer
Publikováno v:
Sarcoma, Vol 2, Iss 1, Pp 29-33 (1998)
Purpose: To determine the efficacy and toxicity of docetaxel as first-line chemotherapy in adult patients with locally advanced and/or metastatic soft tissue sarcoma (STS).
Externí odkaz:
https://doaj.org/article/d7123a8afb494564ab3bb998df4f67ba
Autor:
Bertrand Routy, John Lenehan, Brendan Daisley, Meriem Messaoudene, Kait Al, Corentin Richard, Wilson Miller, Rahima Jamal, Scott Ernst, Diane Logan, Karl Belanger, Luara Martinez- Gili, Benjamin Mullish, Panteleimon Takis, Cecilia Hermosilla Samayoa, Marina Ninkov, Seema Nair Parvathy, Caroline Lambert, Arielle Elkrief, Rejean Lapointe, Mansour Haeryfar, Jeremy Burton, Michael Silverman, Saman Maleki
Publikováno v:
SITC 37th Annual Meeting (SITC 2022)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f2823141e80cb4ff2c9af4429680751
http://hdl.handle.net/10044/1/103665
http://hdl.handle.net/10044/1/103665
Autor:
Michelle Chen, Marie Florescu, Karl Belanger, Vincent-Thierry Taillefer, Jean-Philippe Adam, Catherine Larochelle, Marjorie Pigeon
Publikováno v:
Journal of Oncology Pharmacy Practice. 26:1538-1543
Introduction Nivolumab is a programmed death 1 (PD-1) inhibitor approved by the Food and Drug Administration (FDA) for the treatment of eight different cancers including metastatic melanoma. Immune checkpoint blockade may lead to a range of neurologi
Autor:
Antoine Desilets, Chloe Beland, Valerie Hladky, Steph A. Pang, Arielle Elkrief, Andreea Stepanov, Bertrand Routy, Karl Belanger, Wilson H. Miller, Olivier Larochelle, Rahima Jamal
Publikováno v:
Journal of Clinical Oncology. 40:e21590-e21590
e21590 Background: Uveal melanoma (UM) is a rare subtype of melanoma. Real-world data is needed to guide management since patients with advanced UM were excluded from immune checkpoint inhibition (ICI) phase III clinical trials. Lymphopenia and eleva
Autor:
Wilson H. Miller, Bertrand Routy, Rahima Jamal, D. Scott Ernst, Diane Logan, Khashayar Esfahani, Karl Belanger, Arielle Elkrief, Rejean Lapointe, Pamela Thebault, Mayra Ponce, Seema Nair Parvathy, Meriem Messaoudene, Micheal Silverman, Saman Maleki, John Gordon Lenehan
Publikováno v:
Journal of Clinical Oncology. 40:9533-9533
9533 Background: The gut microbiome has been shown to be a biomarker of response in patients (pts) with melanoma. Strategies to modify the microbiome are currently being investigated. We report the effects of Fecal Microbiota Transplantation (FMT) on
Autor:
David Roberge, Bernard Lemieux, Karl Belanger, Jean-Paul Bahary, Robert Moumdjian, Laura Masucci, F. Berthelet, Marie Florescu, G. Jutras, Nathalie Letarte, Émilie Lemieux-Blanchard, Cynthia Ménard, Jean-Philippe Adam
Publikováno v:
Current Oncology
Volume 25
Issue 1
Pages 3680-39
Volume 25
Issue 1
Pages 3680-39
Procarbazine, lomustine, and vincristine (pcv) significantly improve survival outcomes in lgg (low-grade gliomas). Administration of pcv to lgg patients increased tremendously over the past years as it went from 2 patients per year between 2005 and 2
Autor:
Elie Zeidan, Anis Assad, Laurent Letourneau Guillon, Karl Belanger, Emilie Lemieux Blanchard, Bernard Lemieux, Jean-Paul Bahary, David Roberge, Laura G Masucci, Cynthia Menard, Carole Lambert, Robert Moumdjian, France Berthelet, Meriem Ben-Abdallah, Jacques De Guise, Marie Florescu
Publikováno v:
Neuro Oncol
BACKGROUND In glioblastomas (GBM) patients the first post-radiation MRI is usually difficult to interpret given the post-radiotherapy enhancement and possible pseudo-progression which is present in almost 50% of the patients. METHODS We retrospective
Autor:
Myriam Nait Ajjou, Anis Assad, Laurent Letourneau Guillon, Karl Belanger, Emilie Lemieux Blanchard, Bernard Lemieux, Jean-Paul Bahary, Laura G Masucci, David Roberge, Cynthia Menard, Carole Lambert, Robert Moumdjian, France Berthelet, Meriem Ben-Abdallah, Jacques De Guise, Marie Florescu
Publikováno v:
Neuro Oncol
BACKGROUND Before 2012, Temozolomide (TMZ) was used for low-grade gliomas (LGG) to avoid Lomustine toxicity. After 2012 RTOG data, Procarbazine, Lomustine and Vincristine (PCV) given sequentially with radiotherapy became standard treatment with the s
Autor:
Alan Spatz, Huy Le, Shirin Kazemi, Jida El-Hajjar, Jennifer Elisabeth Friedmann, Pamela Thebault, Jean-Pierre M. Ayoub, Jean-François Cailhier, Léon C van Kempen, Eftihia Cocolakis, Rahima Jamal, Jeanne Dionne, Karl Belanger, Réjean Lapointe, Caroline Lambert, Wilson H. Miller
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-13 (2017)
Journal for immunotherapy of cancer, 5(1):83. BMC
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, 5(1):83. BMC
Journal for Immunotherapy of Cancer
Background Checkpoint blockade with ipilimumab provides long-term survival to a significant proportion of patients with metastatic melanoma. New approaches to increase survival and to predict which patients will benefit from treatment are needed. Thi